Non-Small Cell Lung Cancer
Genomic specialist, Dr. Shelly Gunn, is available to discuss all cases with clinicians. In keeping with our motto, “The Spirit of Excellence”, our new DNA based test offerings are designed to support clinicians practicing Precision Medicine. This personalized approach to testing enables an understanding of the patient’s individual tumor biology at the genomic level.
- Rapid Reporting from Formalin fixed paraffin embed (FFPE) to actionable results.
- Turnaround time is 10 – 14 days
- DNA-based testing clinically indicated for high-risk non-small cell lung cancers
- FFPE Tissue from core biopsy or surgical excision
- Liquid biopsy available from plasma samples
- Technology is FDA-approved COBAS EGFR Testing